Telum Therapeutics — Series A · €18M

Endolysin-antimicrobials biotech secured an €18M Series A co-led by the AMR Action Fund and Inveready to take its lead candidate against drug-resistant hospital-acquired pneumonia into clinical development (press release June 30; most coverage July 1).

LeadAMR Action Fund, Inveready RoundSeries A Announced30 Jun 2026 CityNoáin SectorHealthtech & Bio Source W E N E →

Something wrong? Suggest a correction →